Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Endometriosis – Overview
Endometriosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometriosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometriosis – Companies Involved in Therapeutics Development
Abalone Bio Inc
Aptorum Group Ltd
Bayer AG
BCI Pharma SA
Bol Pharma
Chugai Pharmaceutical Co Ltd
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Egret Therapeutics Inc
Eikonoklastes Therapeutics Inc
ElexoPharm GmbH
Endomet Biosciences Inc
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
Ferring International Center SA
Forendo Pharma Ltd
GeneScience Pharmaceuticals Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hope Medicine Inc
Immunitor Inc
Insud Pharma
Ironwood Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Medibiofarma SL
Mithra Pharmaceuticals SA
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Nippon Shinyaku Co Ltd
Predictive Therapeutics LLC
PregLem SA
SYNG Pharmaceuticals Inc
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB
Endometriosis – Drug Profiles
(drospirenone + estetrol) – Drug Profile
(estradiol + norethindrone acetate + relugolix) – Drug Profile
ABt-140 – Drug Profile
AMY-109 – Drug Profile
BAY-2328065 – Drug Profile
BAY-2395840 – Drug Profile
BOLDPo-08 – Drug Profile
CTX-30916 – Drug Profile
danazol – Drug Profile
drospirenone – Drug Profile
Drug 3 for Endometriosis – Drug Profile
Drug 4 for Endometriosis – Drug Profile
Drug to Inhibit C-Jun for Endometriosis – Drug Profile
DWJ-1483 – Drug Profile
EC-313 – Drug Profile
estradiol sulfamate – Drug Profile
ET-201 – Drug Profile
FOR-6219 – Drug Profile
goserelin – Drug Profile
goserelin acetate – Drug Profile
GXP-1 – Drug Profile
HMI-115 – Drug Profile
IW-3300 – Drug Profile
leuprolide – Drug Profile
leuprolide acetate – Drug Profile
linzagolix choline – Drug Profile
MBF-251 – Drug Profile
medroxyprogesterone acetate SR – Drug Profile
MIA-602 – Drug Profile
MT-2990 – Drug Profile
NA-0116 – Drug Profile
NCE-403 – Drug Profile
NHP-07 – Drug Profile
NLS-1 – Drug Profile
NS-580 – Drug Profile
P2X4 Antagonist – Drug Profile
Peptides for Endometriosis – Drug Profile
progesterone – Drug Profile
quinagolide ER – Drug Profile
Recombinant Protein to Agonize PEDF for Women's Health – Drug Profile
relugolix – Drug Profile
SHR-7280 – Drug Profile
Small Molecule 2 for Endometriosis and Chronic Cough – Drug Profile
Small Molecule to Inhibit Microsomal Prostaglandin E Synthase 1 for Endometriosis – Drug Profile
Small Molecules for Endometriosis, Idiopathic Pulmonary Fibrosis (IPF) and Metastatic Brain Tumor – Drug Profile
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile
Small Molecules to Inhibit CSF1R for Breast Cancer and Endometriosis – Drug Profile
Small Molecules to Inhibit HSD17B1 for Endometriosis – Drug Profile
SP-012 – Drug Profile
SR-16234 – Drug Profile
triptorelin – Drug Profile
triptorelin acetate SR – Drug Profile
TTX-334 – Drug Profile
V-Endo – Drug Profile
VAL-201 – Drug Profile
VAL-301 – Drug Profile
Endometriosis – Dormant Projects
Endometriosis – Discontinued Products
Endometriosis – Product Development Milestones
Featured News & Press Releases
Oct 26, 2022: Enteris BioPharma announces acceptance of abstract for oral presentation at ASRM 2022 Scientific Congress & Expo
Jun 17, 2022: Myovant Sciences and Pfizer announce publication in The Lancet of phase 3 SPIRIT 1 and SPIRIT 2 studies of once-daily Relugolix combination therapy in women with endometriosis-associated pain
Jun 14, 2022: Enteris BioPharma presents data from two clinical studies involving oral formulations of leuprolide at ENDO 2022 Annual Conference
May 25, 2022: ObsEva presents clinical data on oral GnRH antagonist linzagolix at multiple congresses
May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
May 09, 2022: FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree
Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Endometriosis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Endometriosis – Pipeline by Abalone Bio Inc, 2022
Table 14: Endometriosis – Pipeline by Aptorum Group Ltd, 2022
Table 15: Endometriosis – Pipeline by Bayer AG, 2022
Table 16: Endometriosis – Pipeline by BCI Pharma SA, 2022
Table 17: Endometriosis – Pipeline by Bol Pharma, 2022
Table 18: Endometriosis – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Table 19: Endometriosis – Pipeline by Context Therapeutics Inc, 2022
Table 20: Endometriosis – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Table 21: Endometriosis – Pipeline by Egret Therapeutics Inc, 2022
Table 22: Endometriosis – Pipeline by Eikonoklastes Therapeutics Inc, 2022
Table 23: Endometriosis – Pipeline by ElexoPharm GmbH, 2022
Table 24: Endometriosis – Pipeline by Endomet Biosciences Inc, 2022
Table 25: Endometriosis – Pipeline by Enteris BioPharma Inc, 2022
Table 26: Endometriosis – Pipeline by Eurofarma Laboratorios SA, 2022
Table 27: Endometriosis – Pipeline by Evestra Inc, 2022
Table 28: Endometriosis – Pipeline by Evotec SE, 2022
Table 29: Endometriosis – Pipeline by Ferring International Center SA, 2022
Table 30: Endometriosis – Pipeline by Forendo Pharma Ltd, 2022
Table 31: Endometriosis – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Table 32: Endometriosis – Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
Table 33: Endometriosis – Pipeline by Hope Medicine Inc, 2022
Table 34: Endometriosis – Pipeline by Immunitor Inc, 2022
Table 35: Endometriosis – Pipeline by Insud Pharma, 2022
Table 36: Endometriosis – Pipeline by Ironwood Pharmaceuticals Inc, 2022
Table 37: Endometriosis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Table 38: Endometriosis – Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Table 39: Endometriosis – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Table 40: Endometriosis – Pipeline by Medibiofarma SL, 2022
Table 41: Endometriosis – Pipeline by Mithra Pharmaceuticals SA, 2022
Table 42: Endometriosis – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Table 43: Endometriosis – Pipeline by Myovant Sciences Ltd, 2022
Table 44: Endometriosis – Pipeline by Navad Life Sciences Pte Ltd, 2022
Table 45: Endometriosis – Pipeline by Nippon Shinyaku Co Ltd, 2022
Table 46: Endometriosis – Pipeline by Predictive Therapeutics LLC, 2022
Table 47: Endometriosis – Pipeline by PregLem SA, 2022
Table 48: Endometriosis – Pipeline by SYNG Pharmaceuticals Inc, 2022
Table 49: Endometriosis – Pipeline by Synokem Pharmaceuticals Ltd, 2022
Table 50: Endometriosis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 51: Endometriosis – Pipeline by Temple Therapeutics BV, 2022
Table 52: Endometriosis – Pipeline by TiumBio Co Ltd, 2022
Table 53: Endometriosis – Pipeline by ValiRx Plc, 2022
Table 54: Endometriosis – Pipeline by Viramal Ltd, 2022
Table 55: Endometriosis – Pipeline by Xbrane Biopharma AB, 2022
Table 56: Endometriosis – Dormant Projects, 2022
Table 57: Endometriosis – Dormant Projects, 2022 (Contd..1)
Table 58: Endometriosis – Dormant Projects, 2022 (Contd..2)
Table 59: Endometriosis – Dormant Projects, 2022 (Contd..3)
Table 60: Endometriosis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Endometriosis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings